Patients with true mixed growth hormone and prolactin-secreting pituitary adenoma: a case series of 12 patients

References

• Sadoul JL, Thyss A, Freychet P. Invasive mixed growth hormone/prolactin secreting pituitary tumour: complete shrinking by octreotide and bromocriptine, and lack of tumour growth relapse 20 months after octreotide withdrawal. Eur J Endocrinol 1992;126:179–83.
   Google Scholar
• Andersen M, Hagen C, Frystyk J, Schroeder HD. Development of acromegaly in patients with prolactinomas. Eur J Endocrinol 2003;149:17–22.
   PubMed Web of Science ®Google Scholar
• Kiseljak-Vassiliades K, Shafi S, Kerr JM, Phang TL, Kleinschmidt-DeMasters B, Wierman ME. Clinical implications of growth hormone–secreting tumor subtypes. Endocrine 2012;42:18–28.
   PubMed Web of Science ®Google Scholar
• Robert F, Pelletier G, Serri O, Hardy J. Mixed growth hormone and prolactin-secreting human pituitary adenomas: a pathologic, immunocytochemical, ultrastructural, and immunoelectron microscopic study. Hum Pathol 1988;19:1327–34.
   PubMed Web of Science ®Google Scholar
• Lamberts SWJ, Liuzzi A, Chiodini PG, Verde S, Klijn JGM, Birkenháger JC. The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly. Eur J Clin Invest 1982;12:151–5.
   PubMed Web of Science ®Google Scholar
• Scoazec JY, Couvelard A, Reseau T. Classification of pancreatic neuroendocrine tumours: changes made in the 2017 WHO classification of tumours of endocrine organs and perspectives for the future. Ann Pathol 2017;37:444–56.
   PubMed Web of Science ®Google Scholar
• Mete O, Cintosun A, Pressman I, Asa SL. Epidemiology and biomarker profile of pituitary adenohypophysial tumors. Mod Pathol 2018;31:900–9.
   PubMed Web of Science ®Google Scholar
• Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 2003;112:1603–18.
   PubMed Web of Science ®Google Scholar
• Syro LV, Rotondo F, Serna CA, Ortiz LD, Kovacs K. Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary. Pituitary 2017;20:84–92.
   PubMed Web of Science ®Google Scholar
• Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 2007;156:203–16.
   PubMed Web of Science ®Google Scholar
• Thapar K, Kovacs K, Muller PJ. Clinical-pathological correlations of pituitary tumours. Baillieres Clin Endocrinol Metab 1995;9:243–70.
   PubMedGoogle Scholar
• Lv L, Jiang Y, Yin S, et al. Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up. Endocrine 2019;66:310–8.
   PubMed Web of Science ®Google Scholar
• Scheithauer BW, Kovacs KT, Laws ER Jr, Randall RV. Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg 1986;65:733–44.
   PubMed Web of Science ®Google Scholar
• Wu Y, Gao Lu, Guo X, et al. Pituitary adenomas in patients with multiple endocrine neoplasia type 1: a single-center experience in China. Pituitary 2019;22:113–23.
   PubMed Web of Science ®Google Scholar
• Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85:526–9.
   PubMed Web of Science ®Google Scholar
• Klibanski A. Prolactinomas. N Engl J Med 2010;362:1219–26.
   PubMed Web of Science ®Google Scholar
• Delgrange E, Raverot G, Bex M, et al. Giant prolactinomas in women. Eur J Endocrinol 2014;170:31–8.
   PubMed Web of Science ®Google Scholar
• Trouillas J, Roy P, Sturm N, et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 2013;126:123–35.
   PubMed Web of Science ®Google Scholar
• Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993;33:610–8.
   PubMed Web of Science ®Google Scholar
• Mete O, Lopes MB. Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol 2017;28:228–43.
   PubMed Web of Science ®Google Scholar
• Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metabol 1998;83:374–8.
   PubMed Web of Science ®Google Scholar
• Kuhn E, Chanson P. Cabergoline in acromegaly. Pituitary 2017;20:121–8.
   PubMed Web of Science ®Google Scholar
• Berker M, Hazer DB, Yücel T, et al. Complications of endoscopic surgery of the pituitary adenomas: analysis of 570 patients and review of the literature. Pituitary 2012;15:288–300.
   PubMed Web of Science ®Google Scholar
• Dehdashti AR, Ganna A, Karabatsou K, Gentili F. Pure endoscopic endonasal approach for pituitary adenomas: early surgical results in 200 patients and comparison with previous microsurgical series. Neurosurgery 2008;62:1006–17.
   PubMed Web of Science ®Google Scholar
• O'Malley BW, Grady MS, Gabel BC, et al. Comparison of endoscopic and microscopic removal of pituitary adenomas: single-surgeon experience and the learning curve. Neurosurg Focus 2008;25:E10.
   PubMed Web of Science ®Google Scholar
• Gondim JA, Schops M, de Almeida JPC, et al. Endoscopic endonasal transsphenoidal surgery: surgical results of 228 pituitary adenomas treated in a pituitary center. Pituitary 2010;13:68–77.
   PubMed Web of Science ®Google Scholar
• Sala E, Ferrante E, Locatelli M, et al. Diagnostic features and outcome of surgical therapy of acromegalic patients: experience of the last three decades. Hormones 2014;13:95–103.
   PubMedGoogle Scholar
• Rick J, Jahangiri A, Flanigan PM, et al. Growth hormone and prolactin-staining tumors causing acromegaly: a retrospective review of clinical presentations and surgical outcomes. J Neurosurg 2018.
   Web of Science ®Google Scholar
• Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol 2006;65:265–73.
   PubMed Web of Science ®Google Scholar
• Wang M, Mou C, Jiang M, et al. The characteristics of acromegalic patients with hyperprolactinemia and the differences in patients with merely GH-secreting adenomas: clinical analysis of 279 cases. Eur J Endocrinol 2012;166:797–802.
   PubMed Web of Science ®Google Scholar
• Mukai K, Kitamura T, Tamada D, Murata M, Otsuki M, Shimomura I. Relationship of each anterior pituitary hormone deficiency to the size of non-functioning pituitary adenoma in the hospitalized patients. Endocrinol J 2016;63:965–76.
   PubMed Web of Science ®Google Scholar
• Schwyzer L, Starke RM, Jane JA Jr, Oldfield EH. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly. JNS 2015;122:798–802.
   PubMed Web of Science ®Google Scholar
• Molitch ME. Diagnosis and treatment of pituitary adenomas: a review. JAMA 2017;317:516–24.
   PubMed Web of Science ®Google Scholar
• Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003;349:2023–33.
   PubMed Web of Science ®Google Scholar